Mitral-specific cardiac damage score (m-CDS) predicts risk of death in functional mitral regurgitation: a study from the National Echo Database of Australia.


Journal

Open heart
ISSN: 2053-3624
Titre abrégé: Open Heart
Pays: England
ID NLM: 101631219

Informations de publication

Date de publication:
27 Oct 2024
Historique:
received: 18 07 2024
accepted: 08 10 2024
medline: 28 10 2024
pubmed: 28 10 2024
entrez: 27 10 2024
Statut: epublish

Résumé

We set out to explore associations between a 'mitral-specific' cardiac damage score (m-CDS) and survival outcomes in mitral regurgitation (MR) and compare the performance of the m-CDS and an 'aortic-specific' CDS (a-CDS) in patients with MR within the large National Echo Database of Australia. Among 620 831 unique adults investigated with echocardiography, there were 17 658 individuals (3.1%) with moderate or greater functional MR (aged 76±13 years, 51% female) who met inclusion criteria. A randomly selected cohort of 5000 of these patients was used to test seven different CDS models for prediction of subsequent all-cause mortality during an average 3.8-year follow-up. The best-performing CDS model in the The best-performing m-CDS model stratified the full cohort into Stage 0: control (1046 patients, 8%); Stage 1: left atrial damage (3416 patients, 27%); Stage 2: left ventricular damage (3352 patients, 26%); Stage 3: right ventricular damage (1551 patients, 12%) and Stage 4: pulmonary hypertension (3293 patients, 26%). Increasing m-CDS stage was consistently and incrementally associated with both all-cause and cardiovascular mortality at 1 year, 5 years and all-time and remained so after adjustment for increasing age and severity of MR, with a ~35% increase in mortality for each increase in CDS stage (p<0.001). A m-CDS was robustly and incrementally associated with short-, medium- and long-term risk of all-cause and cardiovascular mortality in patients with functional MR in this large registry study.

Identifiants

pubmed: 39462524
pii: openhrt-2024-002841
doi: 10.1136/openhrt-2024-002841
pii:
doi:

Types de publication

Journal Article Multicenter Study

Langues

eng

Sous-ensembles de citation

IM

Informations de copyright

© Author(s) (or their employer(s)) 2024. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.

Déclaration de conflit d'intérêts

Competing interests: None declared.

Auteurs

Avalon Moonen (A)

School of Medicine, The University of Sydney, Sydney, New South Wales, Australia.

David S Celermajer (DS)

School of Medicine, The University of Sydney, Sydney, New South Wales, Australia David.Celermajer@health.nsw.gov.au.
The University of Notre Dame Australia, Fremantle Campus, Fremantle, Perth, Australia.
Heart Research Institute Ltd, Newtown, New South Wales, Australia.

Martin Kc Ng (MK)

School of Medicine, The University of Sydney, Sydney, New South Wales, Australia.
Heart Research Institute Ltd, Newtown, New South Wales, Australia.

Geoff Strange (G)

School of Medicine, The University of Sydney, Sydney, New South Wales, Australia.
The University of Notre Dame Australia, Fremantle Campus, Fremantle, Perth, Australia.

David Playford (D)

The University of Notre Dame Australia, Fremantle Campus, Fremantle, Perth, Australia.

Simon Stewart (S)

The University of Notre Dame Australia, Fremantle Campus, Fremantle, Perth, Australia.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH